HCL Clinical Trials Webinar Series
Join us on May 3 from 12:30-1:30 pm Eastern (11:30 am-12:30 pm Central, 9:30-10:30 am Pacific) for the first webinar in an exciting new series exploring clinical trials in HCL. Through this series, we hope to educate our patient network about current trials and empower them with options.
On May 3, Dr. Robert Kreitman from the National Cancer Institute, NIH, will discuss his open trials in HCL, including their primary aims and eligibility for participation. There will be time for Q&A.
More Information
There are three clinical trials in HCL actively recruiting patients at the NCI. These trials are:
Binimetinib for people with relapsed/refractory BRAF Wild Type HCL and HCL Variant: https://clinicaltrials.gov/study/NCT04322383
Phase I Study of Anti-CD22 Chimeric Receptor T-Cells in patients with relapsed/refractory HCL and HCL Variant: https://clinicaltrials.gov/study/NCT04815356
Encorafenib + Binimetinib for people with BRAF V600E mutated relapsed/refractory HCL: https://clinicaltrials.gov/study/NCT04324112?cond=hairy%20cell%20leukemia&aggFilters=status:rec&rank=6
View all clinical trials in HCL on the HCLF website: